Galapagos NV To Present New In Vitro Pharmacological Data On Its Selective TYK2 Inhibitor, GLPG3667 At ACR Convergence 2025 Conference In Chicago From October 24–29, 2025

Author: Benzinga Newsdesk | October 23, 2025 03:10pm

Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025.

The data show that the in vitro pharmacological profile of GLPG3667 suggests differentiation from other TYK2 inhibitors at their clinical dose regimens.

Key findings from the study include:

• At exposure levels associated with its clinical dose of 150 mg once daily, GLPG3667 showed inhibition of the IFN-α, and IL-23 pathways, comparable to the expected inhibition for the currently approved TYK2 inhibitor at its clinical dose regimens, without a measurable impact on TYK2-independent pathways.
• Inhibition of the IL-12 pathway was more pronounced for GLPG3667 than for the currently approved TYK2 inhibitor. Zasocitinib showed the most sustained inhibition of TYK2-dependent pathways.
• GLPG3667 showed no measurable inhibition of IL-10-mediated signaling up to the highest concentration tested (~10-fold above clinical concentrations) in monocytes, CD4+ T cells and CD19+ B cells, while strong inhibition was observed with two other TYK2 inhibitors at concentrations corresponding to the respective clinical dose regimens.

Posted In: GLPG